IN

Incanthera plc

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Incanthera plc is a therapeutics company specializing in the discovery and development of innovative technologies for the dermatology and oncology sectors. The company leverages sophisticated formulation and targeted delivery platforms to create transformative treatment solutions. Its primary commercial focus is on a dermatological skincare range, branded SKIN + CELL, designed to address previously unmet needs in the market. Originating from the Institute of Cancer Therapeutics at the University of Bradford, Incanthera is dedicated to identifying and commercializing novel therapeutics.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Incanthera plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 08:00
Earnings Release
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
English 21.4 KB
2025-08-06 08:00
Regulatory News Service
SKIN + CELL TO LAUNCH
English 24.3 KB
2025-07-09 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.6 KB
2025-06-30 08:00
Share Issue/Capital Change
Subscription, Directors' Dealing and RPT
English 51.7 KB
2025-06-18 08:00
Environmental & Social Information
New Findings on Protective Effects of Skin + CELL
English 21.1 KB
2025-03-28 08:00
Regulatory News Service
Commercial Update
English 19.0 KB
2025-03-25 16:08
Legal Proceedings Report
Resolution of Allegations of Patent Infringement
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Initiator Pharma A/S Logo
Clinical-stage firm developing drugs for nervous system disorders like ED & trigeminal neuralgia.
Denmark INIT
Innate Pharma Logo
Clinical-stage biotech developing antibodies that harness NK cells to fight cancer.
France IPH
IntegraGen Logo
Genomics specialist providing analyses & SaaS for cancer/rare diseases to researchers & labs.
France ALINT
Inventiva Logo
Develops oral small molecule therapies for fibrosis, oncology, and lysosomal storage disorders.
France IVA
IRLAB Therapeutics Logo
Developing novel treatments for neurodegenerative conditions like Parkinson's disease.
Sweden IRLAB
Isofol Medical Logo
Clinical-stage biotech developing a drug to enhance chemotherapy efficacy for colorectal cancer.
Sweden ISOFOL
IXICO PLC Logo
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom IXI
J. Molner AS Logo
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia JML
Kadimastem Ltd. Logo
Develops off-the-shelf cell therapies for neurodegenerative and metabolic diseases.
Israel KDST
Kancera Logo
Develops drugs targeting the fractalkine axis for severe inflammation and resistant cancers.
Sweden KAN